Status:

COMPLETED

A Controlled Trial of Vertebroplasty for Acute Painful Osteoporotic Fractures

Lead Sponsor:

Optimus Clinical Research

Collaborating Sponsors:

C. R. Bard

Conditions:

Vertebral Compression Fractures

Osteoporotic Vertebral Compression Fractures

Eligibility:

All Genders

60+ years

Phase:

NA

Brief Summary

The objective of this study is to gather data regarding the efficacy, safety and cost-effectiveness of percutaneous vertebroplasty in the acute fracture group with fractures less than 6 weeks old. The...

Detailed Description

The study will be a two arm randomised, blind placebo controlled trial of vertebroplasty for acute (\< 6 weeks) osteoporotic vertebral compression fractures. Patients with substantial pain or immobili...

Eligibility Criteria

Inclusion

  • Inclusion Criteria/Exclusion Criteria:
  • Patient is greater than 60 years of age.
  • Patient has pain which is not adequately controlled by oral analgesia or which has required hospitalisation and prevents early mobilisation
  • Patient has pain from one or two compression fractures of the vertebrae in the areas T4 to L5 confirmed with a sagittal STIR (short tau inversion recovery) and sagittal T1 weighted MRI scan of the spine. Patients with three or more recent fractures are excluded.
  • Clinical history verifies that patient's fracture occurred in the previous 6 weeks.
  • Patient does not have a known coagulopathy. If on warfarin, the INR should be less than 2.5 within the last three days.
  • Patient has no contraindications for conscious sedation.
  • Patient reports pain during ambulation or movement from the compression fracture(s) of at least seven (7) out of ten (10) on a numerical pain scale.
  • Patient has access to a telephone.
  • Patient speaks English well enough to answer all health questions via telephone.
  • Patient has a confirmed diagnosis of osteoporosis via a BMD within 6 months of baseline or a QCT at baseline.
  • Patient does not have a history of debilitating chronic back pain which requires regular analgesia.
  • Patients with chronic back pain who regularly use medication containing any narcotic for a period greater than 6 weeks, that is prior to the acute fracture.
  • Patient does not have significant retropulsed fragment or spinal canal compromise of greater than 20% by retropulsed fragment.
  • Patient has no mental incapacity or dementia that makes him/her unable to give informed consent.
  • Patient has no history of vertebral osteomyelitis.
  • Patient has vertebral body collapse not greater than 60% relative to closest intact vertebra.
  • Patient has no pedicle fractures.
  • Patient has no active local or systemic infection.
  • Patient has not had surgery (within the last 60 days).
  • Patient has no concomitant hip fracture.
  • Patient has no malignant tumour deposit (multiple myeloma), tumour mass, or tumour extension into the epidural space at the level of the fracture to be treated on MRI.
  • Patient does not have severely immunocompromised health status (including any patient who is HIV positive, currently on chemotherapy, taking high doses of long term corticosteroids - defined as a dose of prednisone exceeding 10mg for greater than 3 months in the last 12 months, has a hematologic malignancy, or a transplant recipient.)
  • Patient able to attend face to face visits.

Exclusion

    Key Trial Info

    Start Date :

    November 1 2011

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    May 1 2015

    Estimated Enrollment :

    120 Patients enrolled

    Trial Details

    Trial ID

    NCT01482793

    Start Date

    November 1 2011

    End Date

    May 1 2015

    Last Update

    July 13 2015

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Optimus Clinical Research

    Sydney, New South Wales, Australia, 2217